Core Viewpoint - Fortrea Holdings, Inc. is facing a securities class action lawsuit due to allegations of misleading investors regarding its financial projections and business model viability during the class period from July 3, 2023, to February 28, 2025 [3]. Group 1 - The lawsuit claims that Fortrea overstated projected revenue from Pre-Spin Projects, exaggerated expected cost savings from exiting transition service agreements, and inflated EBITDA targets for 2025 [3]. - Investors are reminded of the August 1, 2025 deadline to seek appointment as lead plaintiff in the class action lawsuit [1][4]. - Wolf Haldenstein Adler Freeman & Herz LLP, the law firm handling the case, has over 125 years of experience in securities litigation and aims to protect the rights of investors [4].

Core Viewpoint - Fortrea Holdings Inc. is facing a federal securities class action lawsuit due to allegations of misleading statements regarding its financial performance and business model, particularly concerning its revenue projections and cost savings [5][3]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is investigating potential claims against Fortrea and has set an August 1, 2025 deadline for investors to seek the role of lead plaintiff in the class action [3]. - Investors who suffered losses exceeding $50,000 in Fortrea between July 3, 2023, and February 28, 2025, are encouraged to contact the firm for legal options [1]. Group 2: Allegations Against Fortrea - The complaint alleges that Fortrea overestimated revenue contributions from Pre-Spin Projects and overstated cost savings from exiting Transition Service Agreements (TSAs), leading to inflated EBITDA targets for 2025 [5]. - The company's public statements regarding its business model and financial prospects were deemed materially false and misleading [5]. Group 3: Stock Performance and Analyst Downgrades - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in its business model and a decline in stock price by $2.73 (12.29%) to $19.48 [6]. - Following the cancellation of two scheduled conferences, Baird Equity Research downgraded Fortrea to neutral on December 6, 2024, resulting in a stock price drop of $1.90 (8.06%) to $21.67 [7]. - Fortrea's fourth quarter and full year 2024 results revealed that its revenue and adjusted EBITDA expectations for 2025 were not aligned with prior forecasts, causing a significant stock price decline of $3.47 (25.05%) to $10.38 on March 3, 2025 [8].

Core Viewpoint - A securities class action lawsuit has been filed against 3D Systems Corporation for allegedly making materially false and misleading statements during the Class Period from August 13, 2024, to May 12, 2025 [1][2]. Financial Performance - 3D Systems reported disappointing financial results for Q4 and full-year 2024, with a non-GAAP EPS of -$0.19, missing consensus by $0.08 per share [9]. - Sales revenue for Q4 2024 was $111 million, down 3.4% year-over-year, and missed estimates by $4.17 million [9]. - Full-year 2024 revenue totaled $440.1 million, reflecting a 10% decline from the prior year, primarily due to weaker hardware system sales [9]. - A $9 million revenue reduction in Q4 was attributed to changes in accounting estimates related to the Regenerative Medicine Program [9]. Stock Price Reaction - Following the announcement of disappointing Q4 results on March 26, 2025, shares of 3D Systems fell by 20.96%, closing at $2.15 per share on March 27, 2025 [3]. - After the May 12, 2025 press release regarding Q1 2025 results, the stock price dropped by $0.68 per share, or 26.6%, closing at $1.87 per share on May 13, 2025 [5]. Issues Raised in the Lawsuit - The lawsuit alleges that 3D Systems understated the impact of weakened customer spending and overstated its resilience amid challenging industry conditions [9]. - Revised milestone criteria in the United Partnership are expected to adversely affect revenues from the Regenerative Medicine Program [9]. - The company's public statements were deemed materially misleading due to these factors [9].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in PepGen between March 7, 2024 and March 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 15, 2025 /PRNewswire/ -- Fa ...

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Hallador Energy Company regarding possible violations of federal securities laws and unlawful business practices [1]. Group 1: Company Developments - On May 23, 2025, Hallador disclosed the termination of its exclusivity agreement with a datacenter developer for a potential power supply deal [1]. - Hallador stated that discussions for an additional exclusivity period are ongoing, along with non-exclusive discussions with other parties [1]. - Following the announcement, Hallador's share price fell by $1.38, from $18.83 on May 22, 2025, to $17.45 on May 23, 2025 [1]. Group 2: Legal Investigation - The investigation by Kirby McInerney LLP focuses on whether Hallador and/or its officers have engaged in unlawful business practices [1]. - Investors who purchased Hallador securities and have information related to the investigation are encouraged to contact the law firm [2].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against DoubleVerify Holdings, Inc. due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by July 21, 2025 [3][5]. Group 1: Allegations Against DoubleVerify - The complaint alleges that DoubleVerify misled investors by failing to disclose that customers were shifting ad spending to closed platforms, where the company's capabilities were limited [5]. - It is claimed that the monetization of DoubleVerify's high-margin Activation Services was hindered by the expensive and time-consuming development of technology for closed platforms [5]. - The complaint states that DoubleVerify's competitors were better positioned to incorporate AI into their offerings, negatively impacting the company's competitive edge and profits [5]. - Allegations include systematic overbilling of customers for ad impressions served to declared bots, which undermined the integrity of DoubleVerify's services [5]. - The company's risk disclosures were characterized as materially false and misleading, presenting adverse facts as mere possibilities [5]. Group 2: Impact of Disclosures - The truth about the alleged fraud was revealed through disclosures in February and March 2025, leading to a significant stock price drop of 36% following disappointing earnings and the suspension of services by a major customer [6]. - A report from Adalytics Research in March 2025 claimed that DoubleVerify's services were ineffective, further damaging investor confidence [6]. Group 3: Legal Proceedings - The lead plaintiff in the class action lawsuit will be the investor with the largest financial interest who is also typical of class members, overseeing the litigation on behalf of the class [7]. - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Fortrea Holdings Inc. for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by August 1, 2025 [3][5]. Group 1: Allegations Against Fortrea - The complaint alleges that Fortrea and its executives made false and misleading statements regarding revenue expectations from Pre-Spin Projects and overstated cost savings from exiting Transitional Service Agreements (TSAs) [5]. - It is claimed that Fortrea's previously announced EBITDA targets for 2025 were inflated, leading to an overstatement of the company's business model viability and financial prospects [5]. - The company's public statements were deemed materially false and misleading at all relevant times [5]. Group 2: Stock Performance and Analyst Downgrades - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in the business model and a stock price drop of $2.73 per share (12.29%) to close at $19.48 [6]. - Following the cancellation of two scheduled conferences, Baird Equity Research downgraded Fortrea to neutral on December 6, 2024, resulting in a stock price decline of $1.90 per share (8.06%) to close at $21.67 [7]. - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not aligned with prior expectations, leading to a significant stock price drop of $3.47 per share (25.05%) to close at $10.38 [8]. Group 3: Legal Proceedings and Investor Actions - Investors who purchased Fortrea securities between July 3, 2023, and February 28, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights [1][3]. - The court-appointed lead plaintiff will be the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [9]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Fortrea's conduct [10].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Red Cat Holdings, Inc. for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by July 21, 2025 [3][5]. Group 1: Allegations Against Red Cat - The complaint alleges that Red Cat and its executives made false and misleading statements regarding the production capacity of the Salt Lake City Facility and the overall value of the SRR Contract [5][8]. - Defendants claimed that the SRR Contract could generate hundreds of millions to over a billion dollars in revenues, which was later contradicted by actual production capabilities [7][13]. - Following disclosures about the facility's actual production capacity being only 100 drones per month, Red Cat's stock price fell by 8.93% [10]. Group 2: Financial Performance and Stock Impact - In Q1 of fiscal year 2025, Red Cat reported losses per share of $0.17, missing consensus estimates by $0.09, and revenue of $2.8 million, missing estimates by $1.07 million [11]. - After announcing a pause in manufacturing due to retooling, Red Cat's stock price dropped by 25.32% over two trading sessions [11]. - Following the Kerrisdale Report, which alleged that the SRR Contract was worth only $20 million to $25 million, Red Cat's stock price fell by 21.54% [14]. Group 3: Company Developments - Red Cat was selected by the U.S. Department of Defense for the SRR Program, which aims to provide small, portable drones to Army platoons [6]. - The company announced that it had won the SRR Contract, projecting potential revenues of $50 million to $79.5 million for fiscal year 2025 [12]. - The Salt Lake City Facility's construction was reported as "substantially completed," with a potential future production capacity of 1,000 drones per month, contingent on further investments [9].

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) between February 27, 2025, to May 26, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Rondolph Ho v. Rocket Pharmaceuticals, Inc., et al. (Case No. 3:25-cv-10049) has been commenced in the United States District Court ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against PepGen Inc. due to allegations of violations of federal securities laws related to misleading statements about the effectiveness and safety of its drug PGN-EDO51 and the CONNECT2 study [3][5]. Group 1: Allegations and Legal Actions - The complaint alleges that PepGen and its executives made false statements regarding the effectiveness and safety of PGN-EDO51, leading to an overstatement of its clinical and commercial prospects [5]. - Investors who suffered losses exceeding $50,000 in PepGen between March 7, 2024, and March 3, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1][3]. - There is an August 11, 2025, deadline for investors to seek the role of lead plaintiff in the federal securities class action against PepGen [3]. Group 2: Clinical Study Results and Stock Performance - On July 30, 2024, PepGen reported "positive clinical data" from the CONNECT1 study, but analysts noted that the results were below expectations, leading to a 32.69% drop in stock price [6][7]. - A clinical hold notice from the FDA on December 16, 2024, raised concerns about the CONNECT2 study, resulting in a 3.63% decline in stock price [8][9]. - Following updates on safety concerns and a temporary pause of the CONNECT2 study on March 4, 2025, PepGen's stock fell by 18.86% [10][11]. - On May 28, 2025, PepGen announced the discontinuation of its DMD programs after PGN-EDO51 failed to achieve target dystrophin levels [12].